our global r&d resources platform is a collaboration of efforts between hepalink r&d center, cytovance® biologics cdmo r&d business teams and various third-party cooperative r&d efforts, which are capable of meeting clinical and market demands. hepalink’s r&d center focuses on the clinical development of its own innovative drugs - heparin derivatives - and provides technical support for our commercialized pharmaceutical products. the cdmo business r&d platform, located in north america provides comprehensive development and manufacturing services for late discovery to commercial stage biologic therapeutic . we also develop a series of first-in-class drug candidates through our new drug portfolio companies, and have gradually opened clinical sites in china to join the international multi-center clinical trials (mrct). additionally, we are working with leading cro providers to advance research and development drug candidates.